INTRODUCTION {#s1}
============

Wilms' tumor, also known as nephroblastoma, is the most common renal malignancy in children \[[@R1], [@R2]\]. The incidence of Wilms' tumor is about 1 in 10,000 children of Western descent \< 15 years of age \[[@R3]\]. Wilms' tumor is less prevalent in China than in Western countries, with an incidence of \~3.3 per million \[[@R4]\]. Dramatic progress has been made in the treatment of children with Wilms' tumor, with overall survival rates exceeding 90% in 2009, compared with about 30% in the 1930s \[[@R5], [@R6]\]. This success has mainly been due to multidisciplinary therapy and multi-institutional clinical trials \[[@R7], [@R8]\]. However, about 25% of affected children cannot be cured by current treatments, and approximately 50% of these children will die of Wilms' tumor despite aggressive re-treatment \[[@R9], [@R10]\].

Wilms' tumor appears to arise from nephrogenic rests, lesions that form when mesenchymal tissue fails to differentiate to nephrons \[[@R11]\]. Although there have been major advances in understanding the pathogenesis of Wilms' tumor, the molecular mechanisms responsible for this differentiation failure are not completely understood. Chromosomal abnormalities are known to promote the formation of Wilms' tumor by stimulating the uncontrolled growth of these undifferentiated cells \[[@R12], [@R13]\]. While a substantial proportion of Wilms' tumor cases are sporadic and unilateral, 1--2% are hereditary \[[@R14]--[@R16]\]. Thus, genetic factors may also be involved in the predisposition to and aggressiveness of Wilms' tumor \[[@R17], [@R18]\].

The Wilms' tumor gene was the first identified suppressor of Wilms' tumor development \[[@R19]\]. Thereafter, several susceptibility genes were found predispose individuals to Wilms' tumor, such as *FWT1* \[[@R20]\], *FWT2* \[[@R21]\], *BRCA2* \[[@R22]\], *TP53* \[[@R23], [@R24]\], *BARD1* \[[@R25]\] and *CTR9* \[[@R26]\]. The LIM domain only 1 (*LMO1*) gene is located at 11p15, and encodes a cysteine-rich two-LIM-domain transcriptional regulator. *LMO1*, along with three paralogues (*LMO2*, *LMO3* and *LMO4*), is a member of the *LMO* gene superfamily. *LMO1* is abundantly expressed in the nervous system and has been implicated in its development \[[@R27]\]. Overexpression of LMO1 was initially found in patients with T-cell acute lymphoblastic leukemia \[[@R28]\]. Although numerous subsequent studies have demonstrated the association of this critical gene with neuroblastoma risk \[[@R29]--[@R31]\], none have investigated the associations between *LMO1* single nucleotide polymorphisms (SNPs) and Wilms' tumor risk.

Four polymorphisms in *LMO1* (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) were found to be associated with the risk of several cancers in a genome-wide association study (GWAS) \[[@R29], [@R32]\]. We speculated that these polymorphisms might also contribute to the risk of Wilms' tumor. Thus, we examined the associations between these *LMO1* polymorphisms and Wilms' tumor risk in Southern Chinese children.

RESULTS {#s2}
=======

Population characteristics {#s2_1}
--------------------------

In total, 145 Wilms' tumor patients and 531 cancer-free controls were included in our analysis. Their demographic characteristics are presented in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. The mean age was 26.17 ± 21.48 months for the Wilms' tumor patients and 29.73 ± 24.86 months for controls. The distributions of age (*P* = 0.725) and gender (*P* = 0.956) did not differ significantly between the cases and controls. Regarding the clinical stages of the cases, 4 (2.76%), 49 (33.79%), 50 (34.48%), 33 (22.76%), and 9 (6.21%) cases were classified into stages I-IV and 'not available', respectively, in accordance with National Wilms Tumor Study-5 criteria \[[@R33]\].

Associations between *LMO1* gene polymorphisms and Wilms' tumor risk {#s2_2}
--------------------------------------------------------------------

We then genotyped the Wilms' tumor patients and cancer-free controls for four *LMO1* gene polymorphisms (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G). The *LMO1* genotype frequencies and their associations with Wilms' tumor risk are listed in Table [1](#T1){ref-type="table"}. The observed genotype frequencies among the controls were all in agreement with Hardy-Weinberg equilibrium. Among the four polymorphisms, only rs1140419 A\>G was associated with Wilms' tumor risk -- the risk was lower for children with the AG genotype than for those with the AA genotype (adjusted odds ratio \[OR\] = 0.62, 95% confidence interval \[CI\] = 0.41--0.94, *P* = 0.024). We further examined the joint effect of these risk genotypes on Wilms' tumor susceptibility. The risk for developing Wilms' tumor was significantly greater in individuals carrying one to four risk genotypes (nucleotide alterations) than in those with no risk genotypes (adjusted OR = 1.84, 95% CI = 1.25--2.69, *P* = 0.002).

###### Associations between *LMO1* gene polymorphisms and Wilms' tumor susceptibility

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Genotype                            Cases\        Controls\     *P*^a^   Crude OR\               *P*         Adjusted OR\            *P*^b^
                                      (*N* = 143)   (*N* = 531)            (95% CI)                            (95% CI) ^b^            
  ----------------------------------- ------------- ------------- -------- ----------------------- ----------- ----------------------- --------
  rs110419 (HWE = 0.248)                                                                                                               

   AA                                 55 (38.46)    159 (29.94)            1.00                                1.00                    

   AG                                 59 (41.26)    275 (51.79)            **0.62 (0.41--0.94)**   **0.024**   **0.62 (0.41--0.94)**   0.024

   GG                                 29 (20.28)    97 (18.27)             0.86 (0.52--1.45)       0.579       0.87 (0.52--1.46)       0.605

   Additive                                                       0.070    0.87 (0.67--1.14)       0.323       0.88 (0.67--1.15)       0.335

   Dominant                           88 (61.54)    372 (70.06)   0.055    0.68 (0.47--1.01)       0.053       0.68 (0.47--1.01)       0.053

   Recessive                          114 (81.73)   434 (81.73)   0.587    1.14 (0.72--1.81)       0.584       1.15 (0.72--1.83)       0.554

  rs4758051 (HWE = 0.199)                                                                                                              

   GG                                 52 (36.36)    194 (36.53)            1.00                                1.00                    

   AG                                 64 (44.76)    242 (45.57)            0.99 (0.65--1.49)       0.949       0.98 (0.65--1.49)       0.936

   AA                                 27 (18.88)    95 (17.89)             1.06 (0.63--1.79)       0.827       1.05 (0.62--1.77)       0.863

   Additive                                                       0.962    1.02 (0.79--1.32)       0.863       1.02 (0.79--1.32)       0.898

   Dominant                           91 (63.64)    337 (63.47)   0.970    1.01 (0.69--1.48)       0.970       1.00 (0.68--1.47)       0.995

   Recessive                          116 (81.12)   436 (82.11)   0.786    1.07 (0.67--1.72)       0.785       1.06 (0.66--1.70)       0.818

  rs10840002 (HWE = 0.070)                                                                                                             

   AA                                 46 (32.17)    182 (34.27)            1.00                                1.00                    

   AG                                 62 (43.36)    240 (45.20)            1.02 (0.67--1.57)       0.920       1.02 (0.67--1.57)       0.929

   GG                                 35 (24.48)    109 (20.53)            1.27 (0.77--2.09)       0.348       1.26 (0.77--2.08)       0.362

   Additive                                                       0.597    1.12 (0.87--1.44)       0.381       1.12 (0.87--1.44)       0.395

   Dominant                           97 (67.83)    349 (65.73)   0.635    1.10 (0.74--1.63)       0.637       1.10 (0.74--1.63)       0.650

   Recessive                          108 (75.52)   422 (79.47)   0.312    1.26 (0.81--1.94)       0.307       1.25 (0.81--1.93)       0.319

  rs204938 (HWE = 0.153)                                                                                                               

   AA                                 94 (65.73)    354 (66.67)            1.00                                1.00                    

   AG                                 42 (29.37)    165 (31.07)            0.96 (0.64--1.44)       0.839       0.96 (0.64--1.44)       0.830

   GG                                 7 (4.90)      12 (2.26)              2.20 (0.84--5.73)       0.108       2.20 (0.84--5.75)       0.109

   Additive                                                       0.280    1.13 (0.81--1.58)       0.481       1.13 (0.80--1.58)       0.487

   Dominant                           49 (34.27)    177 (33.33)   0.834    1.04 (0.71--1.54)       0.833       1.04 (0.70--1.54)       0.842

   Recessive                          136 (95.10)   519 (97.74)   0.114    2.23 (0.86--5.76)       0.099       2.23 (0.86--5.78)       0.099

  Combined effect of risk genotypes                                                                                                    

   0                                  51 (35.66)    268 (50.47)            1.00                                1.00                    

   1--4                               92 (64.34)    263 (49.53)   0.002    **1.84 (1.25--2.69)**   **0.002**   **1.84 (1.25--2.69)**   0.002
  ---------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio; CI: confidence interval; HWE: Hardy--Weinberg equilibrium.

^a^χ^2^ test for genotype distributions between Wilms' tumor patients and controls.

^b^Adjusted for age and gender.

Stratification analysis {#s2_3}
-----------------------

We further evaluated the relationship between the *LMO1* risk genotypes and Wilms' tumor susceptibility in subjects stratified by age, gender, and clinical stage (Table [2](#T2){ref-type="table"}). The stratification analysis indicated that the rs110419 AG/GG genotype was more likely to reduce Wilms' tumor risk in males (crude OR = 0.60, 95% CI = 0.36--0.996, *P* = 0.048), but this association disappeared after adjustment for age and gender (adjusted OR = 0.61, 95% CI = 0.36--1.01, *P* = 0.057). No significant associations between rs110419 A\>G and Wilms' tumor risk were observed in the age or clinical-stage subgroups. The stratification analysis also indicated that the association of one to four risk genotypes with increased Wilms' tumor risk was limited to the subjects who were \>18 months old (adjusted OR = 2.69, 95% CI = 1.57--4.61, *P* = 0.0003), female (adjusted OR = 2.67, 95% CI = 1.47--4.85, *P* = 0.001), and in clinical stages III+IV (adjusted OR = 2.16, 95% CI = 1.31--3.55, *P* = 0.002).

###### Stratification analysis of the associations between risk genotypes and Wilms' tumor susceptibility

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables         rs110419\          OR       *P*                      Adjusted OR^a^   *P*^a^              Risk genotypes\    OR       *P*      Adjusted OR a           *P*^a^                               
                    (cases/controls)                                                                          (cases/controls)                                                                                  
  ----------------- ------------------ -------- ------------------------ ---------------- ------------------- ------------------ -------- -------- ----------------------- ------------ ----------------------- ------------
  Age, months                                                                                                                                                                                                   

  ≤18               24/74              41/159   0.80 (0.45--1.41)        0.433            0.80 (0.45--1.41)   0.434              28/110   37/123   1.18 (0.68--2.06)       0.555        1.17 (0.67--2.04)       0.575

  \>18              31/85              47/213   0.61 (0.36--1.02)        0.057            0.61 (0.36--1.02)   0.059              23/158   55/140   **2.70 (1.58--4.62)**   **0.0003**   **2.69 (1.57--4.61)**   **0.0003**

  Gender                                                                                                                                                                                                        

  Female            23/73              41/160   0.81 (0.46--1.45)        0.486            0.81 (0.45--1.44)   0.468              19/123   45/110   **2.65 (1.46--4.80)**   **0.001**    **2.67 (1.47--4.85)**   **0.001**

  Male              32/86              47/212   **0.60 (0.36--0.996)**   **0.048**        0.61 (0.36--1.01)   0.057              32/145   47/153   1.39 (0.84--2.30)       0.198        1.37 (0.82--2.26)       0.227

  Clinical stages                                                                                                                                                                                               

  I+II              22/159             31/372   0.60 (0.34--1.07)        0.085            0.61 (0.34--1.08)   0.091              23/268   30/263   1.33 (0.75--2.35)       0.327        1.31 (0.74--2.33)       0.358

  III+IV            28/159             53/372   0.81 (0.49--1.33)        0.401            0.81 (0.49--1.32)   0.396              26/268   55/263   **2.16 (1.31--3.54)**   **0.002**    **2.16 (1.31--3.55)**   **0.002**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Adjusted for age and gender.

OR, odds ratio. CI, confidence interval.

Haplotype analysis and false-positive report probability (FPRP) analysis {#s2_4}
------------------------------------------------------------------------

The inferred haplotypes for the *LMO1* gene (in the order of rs110419, rs4758051, rs10840002 and rs204938) and their associations with Wilms' tumor risk are shown in Table [3](#T3){ref-type="table"}. Wilms' tumor risk was greater in GGAG haplotype carriers (OR = 3.23, 95% CI = 1.26--8.26, *P* = 0.014) than in GGAA haplotype carriers. Likewise, the GGGA haplotype was also associated with greater Wilms' tumor risk than GGAA (OR = 3.46, 95% CI = 1.46--8.18, *P* = 0.005).

###### The frequencies of inferred *LMO1* gene haplotypes based on observed genotypes, and their associations with Wilms' tumor susceptibility

  --------------------------------------------------------------------------------------------------------------------
  Haplotypes^a^   Cases\        Controls\      Crude OR\               *P*         Adjusted OR^b^\         *P*^b^
                  (*n* = 286)   (*n* = 1062)   (95% CI)                            (95% CI)                
  --------------- ------------- -------------- ----------------------- ----------- ----------------------- -----------
  GGAA            53 (18.53)    276 (25.99)    1.00                                1.00                    

  GGAG            8 (2.80)      12 (1.13)      **3.23 (1.26--8.26)**   **0.014**   **3.23 (1.26--8.28)**   **0.015**

  GGGA            10 (3.50)     14 (1.32)      **3.46 (1.46--8.18)**   **0.005**   **3.53 (1.49--8.35)**   **0.004**

  GAAA            2 (0.70)      0 (0.00)       /                       /           /                       /

  GAGA            39 (13.64)    149 (14.03)    1.27 (0.81--1.99)       0.306       1.28 (0.81--2.01)       0.293

  GAGG            5 (1.75)      18 (1.69)      1.35 (0.48--3.77)       0.573       1.35 (0.48--3.79)       0.570

  AGAA            73 (25.52)    253 (23.82)    1.40 (0.95--2.06)       0.090       1.41 (0.96--2.07)       0.083

  AGAG            18 (6.29)     60 (5.65)      1.45 (0.80--2.64)       0.222       1.45 (0.80--2.65)       0.223

  AGGA            5 (1.75)      8 (0.75)       3.03 (0.96--9.59)       0.060       2.96 (0.93--9.43)       0.066

  AGGG            1 (0.35)      7 (0.66)       0.69 (0.08--5.73)       0.733       0.72 (0.09--6.00)       0.762

  AAAA            0 (0.00)      3 (0.28)       /                       /           /                       /

  AAGA            48 (16.78)    170 (16.01)    1.37 (0.89--2.10)       0.153       1.36 (0.88--2.09)       0.164

  AAGG            24 (8.39)     92 (8.66)      1.26 (0.74--2.15)       0.390       1.26 (0.74--2.15)       0.395
  --------------------------------------------------------------------------------------------------------------------

^a^The haplotype order is rs110419, rs4758051, rs10840002, rs204938.

^b^Obtained from logistic regression models adjusted for age and gender.

OR, odds ratio. CI, confidence interval.

In the FPRP analysis (Table [4](#T4){ref-type="table"}), due to the small sample size, nearly all of the significant findings disappeared at a prior probability level of 0.1 and an FPRP threshold of 0.2, except for the increased Wilms' tumor risk in carriers of one to four risk genotypes (FPRP = 0.099).

###### False-positive report probability values for the significant findings

  Genotype               Crude OR (95% CI)    *P*^a^   Statistical power^b^   Prior probability                           
  ---------------------- -------------------- -------- ---------------------- ------------------- ------- ------- ------- -------
  *LMO1* rs110419 A\>G                                                                                                    
   AG vs. AA             0.62 (0.41--0.94)    0.024    0.441                  0.140               0.329   0.844   0.982   0.998
  AG/GG vs. AA                                                                                                            
   Males                 0.60 (0.36--0.996)   0.048    0.328                  0.305               0.568   0.935   0.993   0.999
  *Risk genotypes*                                                                                                        
   1--4 vs. 0            1.84 (1.25--2.69)    0.002    0.165                  0.035               0.099   0.546   0.924   0.992
   \>18 months           2.70 (1.58--4.62)    0.0003   0.008                  0.107               0.264   0.798   0.976   0.998
   Females               2.65 (1.46--4.80)    0.001    0.015                  0.164               0.371   0.867   0.985   0.998
   Stage III+IV          2.16 (1.31--3.54)    0.002    0.038                  0.138               0.324   0.841   0.982   0.998
  *Haplotypes*                                                                                                            
   GGAG vs. GGAA         3.23 (1.26--8.26)    0.014    0.065                  0.400               0.667   0.957   0.996   1.000
   GGGA vs. GGAA         3.46 (1.46--8.18)    0.005    0.036                  0.284               0.543   0.929   0.992   0.999

^a^A χ*2* test was used to calculate the genotype frequency distributions.

^b^Statistical power was calculated from the number of observations in the subgroup and the ORs and *P* values in this table.

OR, odds ratio. CI, confidence interval.

DISCUSSION {#s3}
==========

In the present hospital-based case-control study of 145 children with Wilms' tumor and 531 cancer-free controls, we investigated the associations of four GWAS-identified *LMO1* gene polymorphisms with Wilms' tumor susceptibility. We discovered that rs110419 A\>G was associated with Wilms' tumor susceptibility in a Southern Chinese population. To the best of our knowledge, this is the first report of an association between a *LMO1* gene polymorphism and Wilms' tumor susceptibility in Chinese children.

There is overwhelming evidence that *LMO1* is a critical determinant of cancer susceptibility. In a GWAS conducted among individuals of European descent, Wang et al. discovered that four genetic variants of *LMO1* (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) contributed to the tumorigenesis of neuroblastoma \[[@R29]\]. Subsequently, this relationship was confirmed in four other epidemiological studies among people of different ethnicities \[[@R30], [@R32], [@R34], [@R35]\]. Beuten et al. identified an association between another genetic variant (rs442264 A\>G) in the *LMO1* gene and acute lymphoblastic leukemia susceptibility in a population of Caucasian children (163 cases and 251 controls) \[[@R36]\]. Recently, Oldridge et al. found that the rs2168101 G\>T polymorphism in *LMO1* predisposed individuals to neuroblastoma. The authors also performed biological function studies to elucidate the oncogenic role of this polymorphism in tumor cells \[[@R37]\].

Despite the growing body of research demonstrating the associations of *LMO1* gene variants with cancer susceptibility, until now, no study had investigated the relationship between *LMO1* polymorphisms and Wilms' tumor risk. Here, we performed an epidemiologic study on the associations between four *LMO1* gene polymorphisms and Wilms' tumor risk in 145 affected children and 531 healthy children. We found that the rs110419 AG genotype reduced Wilms' tumor risk in the overall analysis, while we did not detect significant associations between the other three polymorphisms and Wilms' tumor risk. However, we found that the predisposition to Wilms' tumor was significantly greater in children with one to four risk genotypes than in those with no risk genotypes. This relationship was significant in children who were \> 18 months old, female, and in clinical stages III+IV, but not in their counterpart subgroups. The above conflicting results may be ascribed to the following: 1) the relatively small sample size, 2) the relatively weak impact of *LMO1* SNPs, and 3) the influence of environmental factors on Wilms' tumor susceptibility.

Our study was the first to investigate the associations of *LMO1* gene polymorphisms with Wilms' tumor risk in a Chinese population. However, several limitations should be considered in the interpretation of our results. Firstly, only 145 patients and 531 controls were included in this analysis. This relatively small sample size inevitably reduced the statistical power, especially for the stratification and FPRP analyses. Secondly, the inherent selection bias could not be completely eliminated, since our study was a hospital-based study with subjects restricted to South China. Thirdly, due to the nature of retrospective studies, some valuable information could not be collected, such as parental exposures and dietary intakes, which diminished the precision of the results. Finally, these four SNPs were identified in a GWAS on neuroblastoma, while the present study dealt with Wilms' tumor. A GWAS regarding *LMO1* gene SNPs and Wilms' tumor remains to be performed.

In conclusion, we determined that the rs110419 AG polymorphism in *LMO1* may reduce the susceptibility to Wilms' tumor in a Southern Chinese population. Well-designed studies with larger sample sizes in different ethnicities should be performed in the future. Furthermore, other *LMO1* gene variants and gene-environment interactions should be investigated to provide essential insights into the etiology of Wilms' tumor.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

Details on the recruited control subjects were reported previously \[[@R38]--[@R42]\]. For the present study, 145 patients with newly diagnosed and histologically confirmed Wilms' tumor were recruited from the Department of Pediatric Urology, Guangzhou Women and Children\'s Medical Center between March 2001 and June 2016, while 531 cancer-free children undergoing routine physical examinations in the same hospital were randomly selected as controls. All the subjects were genetically unrelated ethnic Han Chinese from South China \[[@R24], [@R25], [@R43]\]. The response rate was approximately 90% for Wilms' tumor patients and 95% for cancer-free controls. The current study was approved by the Institutional Review Board of Guangzhou Women and Children\'s Medical Center. Written informed consent was obtained from each participant\'s parents or legal guardians.

Genotyping {#s4_2}
----------

About 2 mL of peripheral blood was collected from each subject for genotyping. Four *LMO1* gene SNPs (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) identified in a GWAS on neuroblastoma were chosen for genotyping \[[@R29]\]. Genomic DNA was isolated from peripheral blood leukocytes with a TIANamp Blood DNA Kit (TianGen Biotech, Beijing, China) \[[@R38], [@R40]\]. A 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) and Taqman real-time PCR were used to genotype the *LMO1* SNPs, as described thoroughly elsewhere \[[@R44], [@R45]\]. To obtain convincing results, we performed the genotyping blindly, not knowing whether each subject was a case or control. We also randomly selected 10% of the samples for repeated genotyping, and the genotype concordance was 100%.

Statistical analysis {#s4_3}
--------------------

Hardy-Weinberg equilibrium was calculated with a goodness-of-fit χ^2^ test for the genotype frequencies in controls. A two-sided χ^2^ test was used to evaluate the differences in demographic variables and genotype frequencies between cases and controls. To estimate the associations between *LMO1* polymorphisms and Wilms' tumor susceptibility, we calculated ORs and 95% CIs using unconditional logistic regression with adjustment for age and gender. We also assessed the associations of the various haplotypes with Wilms' tumor susceptibility \[[@R46]\]. FPRP analysis was performed as described previously \[[@R47], [@R48]\]. *P* \< 0.05 was considered statistically significant. All statistical analyses were performed with SAS software (Version 9.4; SAS Institute, Cary, NC).
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